Ismaili N. Evolving landscape of biomarkers in colorectal cancer: From interleukin-8 to integrated multi-marker strategies. World J Gastrointest Surg 2026; 18(10): 120555 [DOI: 10.4240/wjgs.120555]
Corresponding Author of This Article
Nabil Ismaili, Chairman, Chief Pharmacist, Professor, Department of Medical Oncology, Mohammed VI Faculty of Medicine, Mohammed VI University of Sciences and Health (UM6SS), Mohammed VI Foundation of Sciences and Health (FM6SS), Mohammed Taïeb Naciri Street, Anfa City, Hay Hassan Municipality, Casablanca 82403, Casablanca-Settat, Morocco. nismaili@um6ss.ma
Research Domain of This Article
Oncology
Article-Type of This Article
review-article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Ismaili N. Evolving landscape of biomarkers in colorectal cancer: From interleukin-8 to integrated multi-marker strategies. World J Gastrointest Surg 2026; 18(10): 120555 [DOI: 10.4240/wjgs.120555]
World J Gastrointest Surg. Oct 27, 2026; 18(10): 120555 Published online Oct 27, 2026. doi: 10.4240/wjgs.120555
Evolving landscape of biomarkers in colorectal cancer: From interleukin-8 to integrated multi-marker strategies
Nabil Ismaili
Nabil Ismaili, Department of Medical Oncology, Mohammed VI Faculty of Medicine, Mohammed VI University of Sciences and Health (UM6SS), Mohammed VI Foundation of Sciences and Health (FM6SS), Casablanca 82403, Casablanca-Settat, Morocco
Author contributions: Ismaili N was responsible for conceptualization, methodology, and software validation, formal analysis and investigation, resources, data curation, writing original draft, review and editing, and visualization.
AI contribution statement: We acknowledge the use of generative AI in drafting this manuscript and assume full responsibility for its content. Our usage was limited to DeepSeek and Grammarly for editing and readability, while explicitly excluding ChatGPT and Notebook LM. AI played no role in data handling, analysis, or scientific rationale.
Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.
Corresponding author: Nabil Ismaili, Chairman, Chief Pharmacist, Professor, Department of Medical Oncology, Mohammed VI Faculty of Medicine, Mohammed VI University of Sciences and Health (UM6SS), Mohammed VI Foundation of Sciences and Health (FM6SS), Mohammed Taïeb Naciri Street, Anfa City, Hay Hassan Municipality, Casablanca 82403, Casablanca-Settat, Morocco. nismaili@um6ss.ma
Received: March 3, 2026 Revised: March 18, 2026 Accepted: August 28, 2026 Published online: October 27, 2026 Processing time: 231 Days and 2.5 Hours
Core Tip
Core Tip: Serum interleukin-8 (IL-8) levels are significantly elevated in patients with colorectal cancer and demonstrate moderate diagnostic accuracy (area under the curve, 0.68). Given this modest discriminatory performance and the absence of external validation, IL-8 does not currently meet the criteria for clinical implementation as a standalone diagnostic biomarker. Although IL-8 has shown independent associations in multivariate analyses, its clinical role remains investigational. Within the evolving biomarker landscape, where mismatch repair status, perioperative carcinoembryonic antigen, and postoperative circulating tumor DNA currently have stronger supportive evidence, IL-8 should be regarded as an investigational biomarker requiring prospective validation before clinical integration. No study to date has demonstrated that IL-8-guided strategies improve clinical outcomes in patients with colorectal cancer.
